RT Journal Article
T1 Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.
A1 Bovis, Francesca
A1 Kalincik, Tomas
A1 Lublin, Fred
A1 Cutter, Gary
A1 Malpas, Charles
A1 Horakova, Dana
A1 Havrdova, Eva Kubala
A1 Trojano, Maria
A1 Prat, Alexandre
A1 Girard, Marc
A1 Duquette, Pierre
A1 Onofrj, Marco
A1 Lugaresi, Alessandra
A1 Izquierdo, Guillermo
A1 Eichau, Sara
A1 Patti, Francesco
A1 Terzi, Murat
A1 Grammond, Pierre
A1 Bergamaschi, Roberto
A1 Sola, Patrizia
A1 Ferraro, Diana
A1 Ozakbas, Serkan
A1 Iuliano, Gerardo
A1 Boz, Cavit
A1 Hupperts, Raymond
A1 Grand'Maison, Francois
A1 Oreja-Guevara, Celia
A1 van Pesch, Vincent
A1 Cartechini, Elisabetta
A1 Petersen, Thor
A1 Altintas, Ayse
A1 Soysal, Aysun
A1 Ramo-Tello, Cristina
A1 McCombe, Pamela
A1 Turkoglu, Recai
A1 Butzkueven, Helmut
A1 Wolinsky, Jerry S
A1 Solaro, Claudio
A1 Sormani, Maria Pia
AB To compare the effectiveness of glatiramer acetate (GA) vs intramuscular interferon beta-1a (IFN-β-1a), we applied a previously published statistical method aimed at identifying patients' profiles associated with efficacy of treatments. Data from 2 independent multiple sclerosis datasets, a randomized study (the Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis [CombiRx] trial, evaluating GA vs IFN-β-1a) and an observational cohort extracted from MSBase, were used to build and validate a treatment response score, regressing annualized relapse rates (ARRs) on a set of baseline predictors. The overall ARR ratio of GA to IFN-β-1a in the CombiRx trial was 0.72. The response score (made up of a linear combination of age, sex, relapses in the previous year, disease duration, and Expanded Disability Status Scale score) detected differential response of GA vs IFN-β-1a: in the trial, patients with the largest benefit from GA vs IFN-β-1a (lower score quartile) had an ARR ratio of 0.40 (95% confidence interval [CI] 0.25-0.63), those in the 2 middle quartiles of 0.90 (95% CI 0.61-1.34), and those in the upper quartile of 1.14 (95% CI 0.59-2.18) (heterogeneity p = 0.012); this result was validated on MSBase, with the corresponding ARR ratios of 0.58 (95% CI 0.46-0.72), 0.92 (95% CI 0.77-1.09,) and 1.29 (95% CI 0.97-1.71); heterogeneity p  We demonstrate the possibility of a criterion, based on patients' characteristics, to choose whether to treat with GA or IFN-β-1a. This result, replicated on an independent real-life cohort, may have implications for clinical decisions in everyday clinical practice.
YR 2020
FD 2020-10-06
LK https://hdl.handle.net/10668/27590
UL https://hdl.handle.net/10668/27590
LA en
DS RISalud
RD Apr 4, 2025